The FDA accepted under priority review Stemline Therapeutics' biologics license application for Elzonris, or tagraxofusp, being developed as a treatment for patients with blastic plasmacytoid dendritic cell neoplasm, with an action date of Feb. 21, 2019. A midstage trial showed that the drug prompted a 54% complete response rate in 13 patients.
Stemline's blood cancer drug accepted under priority review status
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.